Clinical Trials · NCT01342042
The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 36
- Start date
- Mar 2011
- Locations
- 1 site, China
- Primary endpoint
- To compare treatment arms in terms of change from baseline to endpoint in HbA1c